Iovance Biotherapeutics missed Q4 EPS estimates by $0.01
Company exceeded Q4 revenue estimates by $4.68 million
Stock is down 45.88% over the past year despite recent gains
Analyst sentiment remains positive with six positive EPS revisions
📖 Full Retelling
Iovance Biotherapeutics (NASDAQ: IOVA) reported fourth quarter results on February 24, 2026, revealing that while the biotechnology company's earnings per share missed analyst estimates, its revenue exceeded forecasts, sending mixed signals to investors about the company's financial performance. The company posted an EPS of -$0.18 for the quarter, slightly below the analyst consensus estimate of -$0.17. However, Iovance Biotherapeutics demonstrated stronger-than-expected revenue generation, reporting $86.71 million compared to the projected $82.03 million. This revenue beat of approximately $4.68 million provided some positive momentum despite the earnings shortfall. The company's stock closed at $2.89 following the announcement, reflecting a volatile year with shares down 45.88% over the past 12 months despite a more recent 17% increase in the last quarter. Despite the mixed quarterly results, analyst sentiment appears cautiously optimistic, with six positive EPS revisions compared to only two negative ones in the past 90 days. According to InvestingPro, Iovance Biotherapeutics maintains a 'good performance' financial health score, suggesting underlying strengths in the company's operations.
Use of living systems and organisms to develop or make useful products
Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists in the field are known as biotechnologists.
The term biotechnology was first...
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Samsung rally nears 200% as AI chip demand accelerates Bitcoin slips below $63k, wipes out 50% from Oct record high AI is artificial but not intelligent, Yardeni says Asia stocks rise as China reopens on a strong note; Hong Kong hit by tech losses (South Africa Philippines Nigeria) Iovance Biotherapeutics earnings missed, revenue topped estimates By Investing.com Earnings Published 02/24/2026, 07:29 AM Iovance Biotherapeutics earnings missed, revenue topped estimates 0 IOVA 0.70% Investing.com - Iovance Biotherapeutics (NASDAQ: IOVA ) reported fourth quarter EPS of $-0.18, worse than the analyst estimate of $-0.17. Revenue for the quarter came in at $86.71M versus the consensus estimate of $82.03M. Iovance Biotherapeutics’s stock price closed at $2.89. It is up 17.00% in the last 3 months and down -45.88% in the last 12 months. Iovance Biotherapeutics saw 6 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Iovance Biotherapeutics’s stock price’s past reactions to earnings here . According to InvestingPro , Iovance Biotherapeutics’s Financial Health score is " good performance ". Check out Iovance Biotherapeutics’s recent earnings performance , and Iovance Biotherapeutics’s financials here . Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
